We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 24, 2020

Effect of Paclitaxel ± Bevacizumab on PFS Rate Among Patients With Relapsed Ovarian Sex Cord–Stromal Tumors

JAMA Oncology


Additional Info

JAMA Oncology
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial
JAMA Oncol 2020 Oct 08;[EPub Ahead of Print], I Ray-Coquard, P Harter, D Lorusso, et al

Further Reading